Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026

Rapport Therapeutics, Inc.

2025-Q2 EPS reported -$1.44

Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.
RAP-219 Phase 2a trial in drug-resistant focal onset seizures fully enrolled; topline results expected September 2025.
Phase 2 trial of RAP-219 in bipolar mania initiated; topline results anticipated first half of 2027.
Cash, equivalents, and short-term investments $260.4M as of June 30, 2025, sufficient to fund operations through end of 2026.
Phase 1 safety: no SAEs; all TEAEs Grade 1 or 2; most common headache (n=12), dry mouth (5), brain fog (5), fatigue (5).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.